Allens has advised Melbourne-based medical research and public health organisation, The Macfarlane Burnet Institute for Medical Research and Public Health, and 360biolabs' management shareholders on the sale of their interests in 360biolabs to BioAgilytix Labs, a US-based contract research organisation, backed by European private equity firm, Cobepa.
360biolabs is a Melbourne-based contract service organisation providing specialist expertise and laboratory services for the development of new therapeutics, vaccines and diagnostics. BioAgilytix Labs is a leading global contract research laboratory specialising in large molecule drug development and bioanalysis. The transaction is expected to strengthen 360biolabs' ability and capacity to support bioanalytical services across all stages, development capabilities and geographies.
Lead Partner and healthcare M&A specialist Emin Altiparmak said, '360biolabs is another example of the exciting commercial opportunities coming out of our Australian medical research institutions. These niche healthcare investment opportunities remain very attractive to investors of all types including private equity sponsors, and so we expect there will be more coming to market in the year or two ahead.'
